Cargando…
Current and future role of biomarkers in Crohn’s disease risk assessment and treatment
BACKGROUND: Crohn’s disease (CD), a chronic inflammatory bowel disease (IBD), occurs in genetically susceptible individuals who develop aberrant immune responses to endoluminal bacteria. Recurrent inflammation increases the risk of several complications. Despite use of a traditional “step-up” therap...
Autores principales: | Tamboli, Cyrus P, Doman, David B, Patel, Amar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132855/ https://www.ncbi.nlm.nih.gov/pubmed/21753895 http://dx.doi.org/10.2147/CEG.S18187 |
Ejemplares similares
-
Palmitoylation in Crohn’s disease: Current status and future directions
por: Cheng, Wei-Xin, et al.
Publicado: (2021) -
Capsule endoscopy: Current status and role in Crohn’s disease
por: Goran, Loredana, et al.
Publicado: (2018) -
Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016) -
Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn’s disease
por: Piotrowicz, Grażyna, et al.
Publicado: (2020) -
The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response
por: Moy, Matthew P., et al.
Publicado: (2016)